Wall Street analysts issued a fresh round of ratings changes on Friday, including notable downgrades for Airbnb (ABNB), Regeneron (REGN), and Cooper Companies (COO), and upgrades for Unity (U) and ...

Regeneron (NASDAQ:REGN) shares fell ~18% to reach a new 52-week low as a Phase 3 trial failure for its antibody therapy itepekimab, developed with Sanofi (SNY) for a lung disorder known as chronic ...

The latest price target for Regeneron Pharmaceuticals (NASDAQ:REGN) was reported by JP Morgan on June 9, 2025. The analyst firm set a price target for $800.00 expecting REGN to rise to within 12 ...

JPMorgan lowered the firm’s price target on Regeneron (REGN ... particularly as we near a number of pipeline readouts, the analyst tells investors in a research note. Published first on TheFly ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has maintained its Overweight rating on Regeneron Pharmaceuticals, Inc. (NASDAQ ...

JPMorgan Chase & Co. currently has an overweight rating on the stock. Regeneron Pharmaceuticals ... One investment analyst has rated the stock with a sell rating, six have issued a hold rating ...

Ulta Beauty ( ULTA) was the best-performing stock in the S&P 500 after the beauty products retailer beat profit and sales ...

At JPMorgan's Investor Day, the bank's leaders talked about how AI is permeating every business, from fraud detection to wealth advice.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price objective dropped by analysts at JPMorgan Chase ... One investment analyst has rated the stock with a sell rating ...

Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Regeneron (REGN) to $1,081 from $1,150 and keeps an Overweight rating on the shares. The firm adjusted its large cap ...